Quantitative Shotgun Proteomics Unveils Candidate Novel Esophageal Adenocarcinoma (EAC)-specific Proteins.
Esophageal cancer is the eighth most common cancer worldwide and the majority of patients have systemic disease at presentation. Esophageal adenocarcinoma (OAC), the predominant subtype in western countries, is largely resistant to current chemotherapy regimens. Selective markers are needed to enhance clinical staging and to allow targeted therapies yet there are minimal proteomic data on this cancer type. After histological review, lysates from OAC and matched normal esophageal and gastric samples from seven patients were subjected to LC MS/MS after tandem mass tag labeling and OFFGEL fractionation. Patient matched samples of OAC, normal esophagus, normal stomach, lymph node metastases and uninvolved lymph nodes were used from an additional 115 patients for verification of expression by immunohistochemistry (IHC).Over six thousand proteins were identified and quantified across samples. Quantitative reproducibility was excellent between technical replicates and a moderate correlation was seen across samples with the same histology. The quantitative accuracy was verified across the dynamic range for seven proteins by immunohistochemistry (IHC) on the originating tissues. Multiple novel tumor-specific candidates are proposed and EPCAM was verified by IHC.This shotgun proteomic study of OAC used a comparative quantitative approach to reveal proteins highly expressed in specific tissue types. Novel tumor-specific proteins are proposed and EPCAM was demonstrated to be specifically overexpressed in primary tumors and lymph node metastases compared with surrounding normal tissues. This candidate and others proposed in this study could be developed as tumor-specific targets for novel clinical staging and therapeutic approaches.
From the ‡Edinburgh Cancer Research Centre at the Institute of Genetics and Molecular Medicine, Edinburgh University; Robert.o'neill@ed.ac.uk.|§Department of Surgery, Royal Infirmary of Edinburgh.
J Robert
0000-0003-2230-7137
JR
O'Neill
¶Department of Human Protein Sciences, Faculty of Medicine, University of Geneva.
Hui-Song
HS
Pak
‖Centre for Medical Informatics, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh.|**MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, Edinburgh University.
Erola
E
Pairo-Castineira
‡‡Department of Pathology, Royal Infirmary of Edinburgh.
Vicki
V
Save
§Department of Surgery, Royal Infirmary of Edinburgh.
Simon
S
Paterson-Brown
§§Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno.
Rudolf
R
Nenutil
§§Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno.
Bořivoj
B
Vojtěšek
‖Centre for Medical Informatics, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh.|**MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, Edinburgh University.
Ian
I
Overton
¶Department of Human Protein Sciences, Faculty of Medicine, University of Geneva.
Alex
A
Scherl
From the ‡Edinburgh Cancer Research Centre at the Institute of Genetics and Molecular Medicine, Edinburgh University.|§§Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno.
Ted R
TR
Hupp
D000230:Adenocarcinoma / Q000378:metabolism*; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism; D004938:Esophageal Neoplasms / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism*; D040901:Proteomics / Q000379:methods
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins